These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 22465920)

  • 1. [Methylarginies-induced endothelial dysfunction in chronic kidney disease].
    Kimura K
    Yakugaku Zasshi; 2012; 132(4):443-8. PubMed ID: 22465920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease.
    Ueda S; Yamagishi SI; Matsumoto Y; Fukami K; Okuda S
    Clin Exp Nephrol; 2007 Jun; 11(2):115-121. PubMed ID: 17593510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New pathways to renal damage: role of ADMA in retarding renal disease progression.
    Ueda S; Yamagishi S; Okuda S
    J Nephrol; 2010; 23(4):377-86. PubMed ID: 20349427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Endothelial (dys)Function, Left Ventricular Structure and Function in Patients with Chronic Kidney Disease.
    Bartnicki P; Kowalczyk M; Franczyk-Skóra B; Baj Z; Rysz J
    Curr Vasc Pharmacol; 2016; 14(4):360-7. PubMed ID: 26759218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADMA and hyperhomocysteinemia.
    Dayal S; Lentz SR
    Vasc Med; 2005 Jul; 10 Suppl 1():S27-33. PubMed ID: 16444866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA.
    Lentz SR; Rodionov RN; Dayal S
    Atheroscler Suppl; 2003 Dec; 4(4):61-5. PubMed ID: 14664904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADMA and oxidative stress.
    Sydow K; Münzel T
    Atheroscler Suppl; 2003 Dec; 4(4):41-51. PubMed ID: 14664902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of eNOS phosphorylation mediates endothelial dysfunction in renal failure: new effect of asymmetric dimethylarginine.
    Kajimoto H; Kai H; Aoki H; Yasuoka S; Anegawa T; Aoki Y; Ueda S; Okuda S; Imaizumi T
    Kidney Int; 2012 Apr; 81(8):762-8. PubMed ID: 22297680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor.
    Böger RH
    Cardiovasc Res; 2003 Oct; 59(4):824-33. PubMed ID: 14553822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical significance of asymmetric dimethylarginine.
    Siroen MP; Teerlink T; Nijveldt RJ; Prins HA; Richir MC; van Leeuwen PA
    Annu Rev Nutr; 2006; 26():203-28. PubMed ID: 16848705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arginine, arginine analogs and nitric oxide production in chronic kidney disease.
    Baylis C
    Nat Clin Pract Nephrol; 2006 Apr; 2(4):209-20. PubMed ID: 16932427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and homoarginine (hArg): the ADMA, SDMA and hArg paradoxes.
    Tsikas D; Bollenbach A; Hanff E; Kayacelebi AA
    Cardiovasc Diabetol; 2018 Jan; 17(1):1. PubMed ID: 29301528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of asymmetric dimethylarginine and endothelial dysfunction.
    Böger RH
    Clin Chem Lab Med; 2003 Nov; 41(11):1467-72. PubMed ID: 14656027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovascular diseases and heart failure in chronic kidney disease.
    Liu X; Xu X; Shang R; Chen Y
    Nitric Oxide; 2018 Aug; 78():113-120. PubMed ID: 29928990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease.
    Ueda S; Yamagishi S; Kaida Y; Okuda S
    Nephrology (Carlton); 2007 Dec; 12(6):582-90. PubMed ID: 17995585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Asymmetric dimethylarginine--a novel cardiovascular risk factor].
    Siroká R; Cibulka R; Rajdl D; Racek J
    Vnitr Lek; 2006 Mar; 52(3):249-55. PubMed ID: 16722156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes.
    Yamagishi S; Ueda S; Okuda S
    Med Hypotheses; 2007; 69(4):922-4. PubMed ID: 17368960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ADMA: its role in vascular disease.
    Cooke JP
    Vasc Med; 2005 Jul; 10 Suppl 1():S11-7. PubMed ID: 16444864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-β1 synthesis.
    Mihout F; Shweke N; Bigé N; Jouanneau C; Dussaule JC; Ronco P; Chatziantoniou C; Boffa JJ
    J Pathol; 2011 Jan; 223(1):37-45. PubMed ID: 20845411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asymmetric dimethylarginine and angiopoietin-like protein-2 are independent predictors of cardiovascular risk in pre-dialysis non-diabetic chronic kidney disease patients.
    Ashokachakkaravarthy K; Rajappa M; Parameswaran S; Satheesh S; Priyadarshini G; Mohan Raj PS; Revathy G; Priyadarssini M
    Int Urol Nephrol; 2020 Jul; 52(7):1321-1328. PubMed ID: 32409974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.